Breaking News, Collaborations & Alliances

BerGenBio, Tempus Partner to Advance NSCLC Treatment

Aim to improve outcomes for NSCLC patients with STK11 mutations.

Author Image

By: Charlie Sternberg

Associate Editor

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, has entered a collaboration with Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, to advance the clinical development of BerGenBio’s selective AXL inhibitor bemcentinib in first line (1L) Non-Small Cell Lung Cancer (NSCLC) patients with STK11 mutations (STK11m).   BerGenBio’s on-going BGBC0...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters